| Erdafitinib in locally advanced or metastatic urothelial carcinoma Y Loriot, A Necchi, SH Park, J Garcia-Donas, R Huddart, E Burgess, ... New England Journal of Medicine 381 (4), 338-348, 2019 | 1289 | 2019 |
| Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial RJ Motzer, TE Hutson, H Glen, MD Michaelson, A Molina, T Eisen, ... The lancet oncology 16 (15), 1473-1482, 2015 | 1091 | 2015 |
| Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3 … BI Rini, T Powles, MB Atkins, B Escudier, DF McDermott, C Suarez, ... The Lancet 393 (10189), 2404-2415, 2019 | 1005 | 2019 |
| Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4 J Albanell, J Codony, A Rovira, B Mellado, P Gascón New Trends in Cancer for the 21 st Century: Proceedings of the International …, 2003 | 342 | 2003 |
| Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy International Prognostic Factors Study Group Journal of Clinical Oncology 28 (33), 4906-4911, 2010 | 311 | 2010 |
| Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre … J Garcia-Donas, E Esteban, LJ Leandro-García, DE Castellano, ... The lancet oncology 12 (12), 1143-1150, 2011 | 301 | 2011 |
| Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution … V Conteduca, D Wetterskog, MTA Sharabiani, E Grande, ... Annals of Oncology 28 (7), 1508-1516, 2017 | 281 | 2017 |
| Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study J Aparicio, JR Germà, XG del Muro, P Maroto, JA Arranz, A Sáenz, ... Journal of clinical oncology 23 (34), 8717-8723, 2005 | 265 | 2005 |
| Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer KN Chi, D Rathkopf, MR Smith, E Efstathiou, G Attard, D Olmos, JY Lee, ... Journal of Clinical Oncology 41 (18), 3339-3351, 2023 | 235 | 2023 |
| Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results P Sharma, A Siefker-Radtke, F de Braud, U Basso, E Calvo, P Bono, ... Journal of Clinical Oncology 37 (19), 1608-1616, 2019 | 232 | 2019 |
| Interleukin 6, a nuclear factor-κB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-κB inhibition by PS-1145 enhances … J Domingo-Domenech, C Oliva, A Rovira, J Codony-Servat, M Bosch, ... Clinical cancer research 12 (18), 5578-5586, 2006 | 198 | 2006 |
| Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. B Mellado, D Colomer, T Castel, M Munoz, E Carballo, M Galan, ... Journal of clinical oncology 14 (7), 2091-2097, 1996 | 198 | 1996 |
| Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial MR Smith, HI Scher, S Sandhu, E Efstathiou, PN Lara, EY Yu, DJ George, ... The Lancet Oncology 23 (3), 362-373, 2022 | 178 | 2022 |
| Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer M Marín-Aguilera, J Codony-Servat, Ò Reig, JJ Lozano, PL Fernández, ... Molecular cancer therapeutics 13 (5), 1270-1284, 2014 | 176 | 2014 |
| Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial T Powles, KC Yuen, S Gillessen, EE Kadel Iii, D Rathkopf, N Matsubara, ... Nature medicine 28 (1), 144-153, 2022 | 174 | 2022 |
| Telomerase activity is repressed during differentiation of maturation-sensitive but not resistant human tumor cell lines J Albanell, W Han, B Mellado, R Gunawardane, HI Scher, E Dmitrovsky, ... Cancer research 56 (7), 1503-1508, 1996 | 165 | 1996 |
| Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse J Domingo-Domenech, B Mellado, B Ferrer, D Truan, J Codony-Servat, ... British journal of cancer 93 (11), 1285-1294, 2005 | 162 | 2005 |
| Immunohistochemical staining for p16 and p53 in premalignant and malignant epithelial lesions of the vulva M Santos, C Montagut, B Mellado, Á García, SR y Cajal, A Cardesa, ... International journal of gynecological pathology 23 (3), 206-214, 2004 | 154 | 2004 |
| Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study AO Siefker-Radtke, A Necchi, SH Park, J García-Donas, RA Huddart, ... The lancet oncology 23 (2), 248-258, 2022 | 142 | 2022 |
| Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast … J Bellmunt, JL Gonzalez-Larriba, C Prior, P Maroto, J Carles, ... Annals of oncology 22 (12), 2646-2653, 2011 | 138 | 2011 |